REMIT-UC: Real-World Effectiveness and Safety of Tofacitinib for Moderate-to-Severely Active Ulcerative ColitisChristopher Ma, Talat Bessissow, Sanjay K. Murthy et al.|The American Journal of Gastroenterology|2022Cited by 45
Real-world experience and long-term outcomes of a mandatory non-medical switch of adalimumab originator to biosimilars in inflammatory bowel diseaseJeremy Liu Chen Kiow, Greg Rosenfeld, Thomas Hoang et al.|World Journal of Gastroenterology|2024Cited by 9